Hemophilia A Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutica

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia A pipeline constitutes 40+ key companies continuously working towards developing 40+ Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hemophilia A Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.

The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hemophilia A Pipeline Report: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hemophilia A treatment therapies with a considerable amount of success over the years.
• Hemophilia A companies working in the treatment market are Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutica, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceutic als, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment
• Emerging Hemophilia A therapies in the different phases of clinical trials are- Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.
• In September 2022, Giroctocogene fitelparvovec is an investigational gene therapy for people with moderately to severely severe haemophilia A, according to a recent announcement from Pfizer and Sangamo Therapeutics. A crucial readout is predicted for the first half of 2024, and all trial sites are scheduled to be operational by the end of 2022
• In March 2022, ASC618 was given Fast Track designation by the Food and Drug Administration (FDA) for the treatment of haemophilia A
• In May 2022, The Phase III trial evaluating the security and efficiency of SB-525 (giroctocogene fitelparvovec), an investigational gene treatment for haemophilia A, has been unfrozen by the US Food and Drug Administration (FDA)
• In January 2022, In order to collaborate on the research and development of an in vivo gene editing therapy for haemophilia A, 2seventy Bio has entered into an option and licence agreement with Novo Nordisk. This arrangement expands on the two companies' current fruitful multi-year research collaboration
• In November 2021, The pivotal phase III AFFINE study with giroctocogene fitelparvovec (SB-525 or PF07055480) and the Pfizer/Sangamo haemophilia A gene therapy programme have been placed on clinical hold pending FDA assessment of a proposed protocol revision
• In August 2020, In order to assess the clinical effectiveness and safety of a single IV infusion of PF-07055480/giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe haemophilia A (FVIII:C1%) for the duration of the study's five years, Pfizer started a pivotal Phase III study
Hemophilia A Overview
A genetic bleeding illness termed haemophilia A, often called classical haemophilia, is brought on by low amounts of a bloodprotein called factor VIII. Those who have haemophilia A will bleed more than usual following an operation, dental procedure, or other trauma.

Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:
• Research program: Gene Therapies Generation Bio
• P-FVIII-101: Poseida Therapeutics
• ET3 lentiviral gene therapy: Expression Therapeutics
• NXT007: Chugai Pharmaceutica
• ASC618: ASC Therapeutics
• SelectAte: Ascension
• STSP-0601: Staidson (Beijing) Biopharmaceutic als
• TQG 203: Chia Tai Tianqing Pharmaceutical Group
• Mim8: Novo Nordisk
• Giroctocogene fitelparvovec: Pfizer

Hemophilia A Route of Administration
Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hemophilia A Molecule Type
Hemophilia A Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Hemophilia A Pipeline Therapeutics Assessment
• Hemophilia A Assessment by Product Type
• Hemophilia A By Stage and Product Type
• Hemophilia A Assessment by Route of Administration
• Hemophilia A By Stage and Route of Administration
• Hemophilia A Assessment by Molecule Type
• Hemophilia A by Stage and Molecule Type

DelveInsight's Hemophilia A Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies at:
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hemophilia A Therapeutics Market include:
Key companies developing therapies for Hemophilia A are - Intellia tx, Amarna therapeutics, Expression Therapeutics, GC Pharma, Chameleon Biosciences, Pfizer, UBI Pharma, GeneVentiv, Chia Tai Tianqing Pharmaceutical Group, Bayer, ASC Therapeutics, Catalyst Biosciences, Staidson Beijing BioPharmaceuticals, Spark Therapeutics, CSL Behring, Sanofi, Novo Nordisk, Centessa Pharmaceuticals, OPKO Health, Freeline Therapeutics, Spark Therapeutics, Novo Nordisk, Asklepios BioPharmaceutical, Belief Biomed, ASC Therapeutics, uniQure, Sanofi, Bioverativ, and others.

Hemophilia A Pipeline Analysis:
The Hemophilia A pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
• Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hemophilia A drugs and therapies-
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia A Pipeline Market Drivers
• Increasing number of hemophilic patients worldwide, increasing development of novel therapies, increasing diagnostic rate are some of the important factors that are fueling the Hemophilia A Market.

Hemophilia A Pipeline Market Barriers
• However, side effects associated with the plasma derived products, high cost of recombinant products and other factors are creating obstacles in the Hemophilia A Market growth.

Scope of Hemophilia A Pipeline Drug Insight
• Coverage: Global
• Key Hemophilia A Companies: Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutica, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceutic als, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
• Key Hemophilia A Therapies: Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers

Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hemophilia A Report Introduction
2. Hemophilia A Executive Summary
3. Hemophilia A Overview
4. Hemophilia A- Analytical Perspective In-depth Commercial Assessment
5. Hemophilia A Pipeline Therapeutics
6. Hemophilia A Late Stage Products (Phase II/III)
7. Hemophilia A Mid Stage Products (Phase II)
8. Hemophilia A Early Stage Products (Phase I)
9. Hemophilia A Preclinical Stage Products
10. Hemophilia A Therapeutics Assessment
11. Hemophilia A Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hemophilia A Key Companies
14. Hemophilia A Key Products
15. Hemophilia A Unmet Needs
16 . Hemophilia A Market Drivers and Barriers
17. Hemophilia A Future Perspectives and Conclusion
18. Hemophilia A Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Hemophilia A Market https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hemophilia A-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Hemophilia A Epidemiology https://www.delveinsight.com/report-store/hemophilia-a-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hemophilia A Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.